IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treatment... IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.
- Mechanism
- Curator reviewed
IMC-1C11 is a chimerized antibody that targets the KDR receptor (also referred to as VEGFr) on vascular endothelial cells by inhibiting binding of the essential ligand, vascular endothelial growth factor (VEGF), to its receptor. KDR is a key receptor associated with tumor angiogenesis. As solid tumors cannot grow efficiently without new blood supply, use of IMC-1C11 results in the inhibition of tumor growth and death of tumor cells by apoptosis.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
- Code names
- IMC-1C11
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with IMC-1C11, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account